<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128192</url>
  </required_header>
  <id_info>
    <org_study_id>SOM230Novartis/VMRF</org_study_id>
    <nct_id>NCT01128192</nct_id>
  </id_info>
  <brief_title>Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers</brief_title>
  <acronym>Pasireotide</acronym>
  <official_title>Phase 2, Double-Blind, Randomized, Single Center Trial to Assess the Mechanism(s) Responsible for the Effect of the Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers. Version #2 05/09/2009</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert R. Henry, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will attempt to find out why in early studies in healthy volunteers,
      injections under the skin of pasireotide were associated with temporary increases in both
      fasting and post-meal glucose levels, along with possible increases in insulin and glucagon
      levels. Glucose refers to the amount of sugar in your blood and insulin and glucagon levels
      are amounts of hormones that lower and raise blood sugar.

      The purpose of the study is to evaluate the effects of pasireotide on insulin resistance and
      secretion. Insulin is a natural hormone made by the pancreas (a gland inside the abdomen)
      that controls the level of sugar in the blood. Insulin permits cells to use sugar for energy.
      Insulin resistance is the condition in which higher than normal amounts of insulin are
      necessary to allow the sugar to enter the cells. Insulin secretion refers to the amount of
      insulin produced by the body and released in the blood. Glucagon is a hormone (chemical
      substance produced by the pancreas gland in the body) which increases blood glucose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2, double-blinded, single-center study to assess the effects of pasireotide
      on insulin secretion and glucose metabolism in healthy male volunteers. Subjects who had
      given written informed consent and had been shown to satisfy the inclusion and exclusion
      criteria underwent baseline tests. An oral glucose tolerance test (OGTT) was administered on
      Day 1. If the OGTT results confirmed normal glycemia, the subject continued with baseline
      testing on Day 2 (2-step hyperglycemic clamp test with arginine stimulation) and Day 3
      (2-step hyperinsulinemic euglycemic clamp (HEC) test with [3-3H]glucose). Each subject was
      then randomized into 1 of 3 dose groups: 600 µg twice daily (bid) delivered subcutaneously ,
      pasireotide 900 µg bid delivered subcutaneously, or pasireotide 1200 µg bid delivered
      subcutaneously. Subcutaneous injections of pasireotide were given twice daily from Days 3-10
      (for 8 consecutive days, starting from the evening of Day 3 and up to the morning injection
      on Day 10). On Study Days 8-10, the last 3 days of treatment with the pasireotide injections,
      the tests performed at Baseline (ie, the OGTT; the 2-step hyperglycemic clamp test with
      arginine stimulation; and the 2-step HEC test with [3-3H] glucose) were repeated. Subjects
      returned for a post-study safety follow-up visit 5 to 7 days after the last injection of the
      study drug and an H&amp;P and safety labs (including a fasting glucose level) was performed. In
      addition, depending on subject convenience, a 3rd OGTT was either performed on this visit or
      was performed on another occasion convenient for subjects, in order to confirm that subjects'
      OGTT status had returned to baseline levels.

      This additional post-study OGTT was added in a protocol amendment. Those subjects who
      completed the clinical trial and the follow-up visit before the amendment was approved were
      contacted and asked to return for another follow-up visit. The optional post-study OGTT was
      voluntary and subjects could choose not to participate. In order to reduce the severity of
      gastrointestinal adverse events (AEs), the protocol was amended (while keeping the blind
      intact) on 08 December 2009 to discontinue the pasireotide 1200 µg bid arm. The randomization
      scheme was subsequently adjusted to assign subjects in a 1:1 ratio to the 2 remaining arms:
      pasireotide 600 µg bid and pasireotide 900 µg bid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Basal Level</measure>
    <time_frame>-30 min and -15 min on Day 2 and Day 9</time_frame>
    <description>Change from Day 2 and Day 9 of insulin basal levels (2-step hyperglycemic clamp test with arginine stimulation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Area Under the Curve (AUC) of Plasma Insulin Level 0-10mins, 10-180mins, 0-180mins During Hyperglycemic Clamp</measure>
    <time_frame>0-10 mins, 10-180 mins, 0-180 mins (Day 2 and Day 9)</time_frame>
    <description>Blood samples were taken at -30 min, -15 min, 0 min, 15 min, 30 min, 45 min, 60 min, 75 min, 90 min, 105 min, 120 min, 135 min, 150 min, 165 min, 180 min to assess the plasma insulin levels during Hyperglycemic Clamp (2-step hyperglycemic clamp test with arginine stimulation). The mean change in plasma insulin levels from Day 2 to Day 9 were calculated as Values on Day 9 - Values on Day 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Basal Endogenous Glucose Production (EGP)</measure>
    <time_frame>Day 3 and Day 10</time_frame>
    <description>Change from Day 3 and Day 10 of Basal EGP (Hyperinsulinemic-Euglycemic Clamp)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Low Dose % Endogenous Glucose Production (EGP) Inhibition</measure>
    <time_frame>Day 3 and Day 10</time_frame>
    <description>Change from Day 3 and Day 10 of low dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in High Dose % Endogenous Glucose Production (EGP) Inhibition</measure>
    <time_frame>Day 3 and Day 10</time_frame>
    <description>Change from Day 3 and Day 10 of high dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Low-Dose Glucose Disposal Rate (GDR)</measure>
    <time_frame>Day 3 and Day 10</time_frame>
    <description>Change from Day 3 and Day 10 in Low-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in High-Dose Glucose Disposal Rate (GDR)</measure>
    <time_frame>Day 3 and Day 10</time_frame>
    <description>Change from Day 3 and Day 10 in High-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose Level</measure>
    <time_frame>-30 minutes on Day 1 and -30 minutes on Day 8</time_frame>
    <description>An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at
-30 min to assess the fasting plasma glucose level. The mean change in fasting plasma glucose level from Day 1 to Day 8 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Area Under the Curve (AUC) of Plasma Glucose 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>0-30 mins, 30-180 mins, 0-180 mins (Day 1 and Day 8)</time_frame>
    <description>Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma glucose level. The mean change in plasma glucose level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Fasting Plasma Insulin Level</measure>
    <time_frame>-30 minutes on Day 1 and -30 minutes on Day 8</time_frame>
    <description>An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at -30 min to assess the fasting plasma insulin level. The mean change in fasting plasma insulin level from Day 1 to Day 8 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Area Under the Curve (AUC) of Plasma Insulin 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>0-30 mins, 30-180 mins, 0-180 mins (Day 1 and Day 8)</time_frame>
    <description>Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma insulin level. The mean change in plasma insulin level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Pasireotide 600 µg sc bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=19. Pasireotide 600 µg sc bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pasireotide 900 µg sc bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=19. Pasireotide 900 µg sc bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pasireotide 1200 µg sc bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pasireotide</intervention_name>
    <description>Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.</description>
    <arm_group_label>Pasireotide 600 µg sc bid</arm_group_label>
    <arm_group_label>Pasireotide 900 µg sc bid</arm_group_label>
    <arm_group_label>Pasireotide 1200 µg sc bid</arm_group_label>
    <other_name>SOM230</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lean, healthy, non-diabetic male.

        Exclusion Criteria:

          -  Family history of diabetes, BMI over 25.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert R Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Medical Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMR Center for Metabolic Research VASDHS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vacmr.org</url>
    <description>Study site Web site</description>
  </link>
  <results_reference>
    <citation>Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013 Aug;98(8):3446-53. doi: 10.1210/jc.2013-1771. Epub 2013 Jun 3.</citation>
    <PMID>23733372</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <results_first_submitted>July 26, 2013</results_first_submitted>
  <results_first_submitted_qc>December 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 25, 2014</results_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Veterans Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Robert R. Henry, MD</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were healthy men aged 18–50 years with a body mass index (BMI) ≤25 kg/m2 who came to the VA San Diego Healthcare System Metabolic Research medical clinic. Recruitment occurred between August of 2009 until March 2010.</recruitment_details>
      <pre_assignment_details>Participants were excluded if they had a family history of diabetes or a baseline diagnosis of impaired glucose tolerance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pasireotide 600 μg sc Bid</title>
          <description>19 healthy male volunteers were randomized to receive Pasireotide 600 μg (n=19). All participants completed the study.</description>
        </group>
        <group group_id="P2">
          <title>Pasireotide 900 μg sc Bid</title>
          <description>19 healthy male volunteers were randomized to receive Pasireotide 900 μg (n=19). All participants completed the study.</description>
        </group>
        <group group_id="P3">
          <title>Pasireotide 1200 μg sc Bid</title>
          <description>7 healthy male volunteers were randomized to receive Pasireotide 1200 μg (n=7). This arm was used in safety analysis only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Nondiabetic males, aged 18-50 years with body mass index (BMI) ≤ 25. Subjects were not to have any family history of diabetes and no diagnosis of impaired glucose tolerance or gallstone disease.</population>
      <group_list>
        <group group_id="B1">
          <title>Pasireotide 600 μg sc Bid</title>
          <description>Pasireotide 600 μg sc bid n=19</description>
        </group>
        <group group_id="B2">
          <title>Pasireotide 900 μg sc Bid</title>
          <description>Pasireotide 900 μg sc bid n=19</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="4.6"/>
                    <measurement group_id="B2" value="24.6" spread="6.1"/>
                    <measurement group_id="B3" value="24.45" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Nondiabetic males, aged 18-50 years with body mass index (BMI) ≤ 25. Subjects were not to have any family history of diabetes and no diagnosis of impaired glucose tolerance or gallstone disease.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index BMI (kg/m2)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.30" spread="1.61"/>
                    <measurement group_id="B2" value="23.68" spread="2.04"/>
                    <measurement group_id="B3" value="23.49" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.67" spread="8.11"/>
                    <measurement group_id="B2" value="74.49" spread="8.41"/>
                    <measurement group_id="B3" value="75.08" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose Level</title>
        <description>An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at
-30 min to assess the fasting plasma glucose level. The mean change in fasting plasma glucose level from Day 1 to Day 8 was assessed.</description>
        <time_frame>-30 minutes on Day 1 and -30 minutes on Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose Level</title>
          <description>An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at
-30 min to assess the fasting plasma glucose level. The mean change in fasting plasma glucose level from Day 1 to Day 8 was assessed.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.36"/>
                    <measurement group_id="O2" value="0.12" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose level</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.240</p_value>
            <p_value_desc>Two sided P value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma glucose level</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.339</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Area Under the Curve (AUC) of Plasma Glucose 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)</title>
        <description>Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma glucose level. The mean change in plasma glucose level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1.</description>
        <time_frame>0-30 mins, 30-180 mins, 0-180 mins (Day 1 and Day 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Area Under the Curve (AUC) of Plasma Glucose 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)</title>
          <description>Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma glucose level. The mean change in plasma glucose level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1.</description>
          <units>h*mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.43"/>
                    <measurement group_id="O2" value="-0.86" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 30-180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.72" spread="4.23"/>
                    <measurement group_id="O2" value="12.35" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.29" spread="4.02"/>
                    <measurement group_id="O2" value="11.49" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-30 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 30-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P Value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P Value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-30 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 30-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Fasting Plasma Insulin Level</title>
        <description>An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at -30 min to assess the fasting plasma insulin level. The mean change in fasting plasma insulin level from Day 1 to Day 8 was assessed.</description>
        <time_frame>-30 minutes on Day 1 and -30 minutes on Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Fasting Plasma Insulin Level</title>
          <description>An Oral Glucose Tolerance Test was performed at Day 1 (baseline) and Day 8 (post-treatment). Samples were taken at -30 min to assess the fasting plasma insulin level. The mean change in fasting plasma insulin level from Day 1 to Day 8 was assessed.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.62" spread="11.17"/>
                    <measurement group_id="O2" value="-11.69" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma insulin level</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in fasting plasma insulin level</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Area Under the Curve (AUC) of Plasma Insulin 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)</title>
        <description>Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma insulin level. The mean change in plasma insulin level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1</description>
        <time_frame>0-30 mins, 30-180 mins, 0-180 mins (Day 1 and Day 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline OGTT was conducted on Day 1 (pre-treatment) and a post-treatment OGTT was conducted on Day 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Area Under the Curve (AUC) of Plasma Insulin 0-30mins, 30-180mins, 0-180mins During Oral Glucose Tolerance Test (OGTT)</title>
          <description>Blood samples were taken at -30 min, 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min to assess the plasma insulin level. The mean change in plasma insulin level from Day 1 to Day 8 were calculated as Values on Day 8 - Values on Day 1</description>
          <units>h*pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-104.18" spread="90.60"/>
                    <measurement group_id="O2" value="-100.90" spread="68.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 30-180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-184.96" spread="126.57"/>
                    <measurement group_id="O2" value="-262.15" spread="158.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-289.14" spread="162.54"/>
                    <measurement group_id="O2" value="-363.06" spread="191.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-30 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 30-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-30 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 30-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Basal Level</title>
        <description>Change from Day 2 and Day 9 of insulin basal levels (2-step hyperglycemic clamp test with arginine stimulation)</description>
        <time_frame>-30 min and -15 min on Day 2 and Day 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline hyperglycemic clamp test was conducted on Day 2 (pre-treatment) and a post-treatment hyperglycemic clamp was conducted on Day 9.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline hyperglycemic clamp test was conducted on Day 2 (pre-treatment) and a post-treatment hyperglycemic clamp was conducted on Day 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Basal Level</title>
          <description>Change from Day 2 and Day 9 of insulin basal levels (2-step hyperglycemic clamp test with arginine stimulation)</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.37" spread="10.42"/>
                    <measurement group_id="O2" value="-29.60" spread="16.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Baseline Insulin Level</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Baseline Insulin Level</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Area Under the Curve (AUC) of Plasma Insulin Level 0-10mins, 10-180mins, 0-180mins During Hyperglycemic Clamp</title>
        <description>Blood samples were taken at -30 min, -15 min, 0 min, 15 min, 30 min, 45 min, 60 min, 75 min, 90 min, 105 min, 120 min, 135 min, 150 min, 165 min, 180 min to assess the plasma insulin levels during Hyperglycemic Clamp (2-step hyperglycemic clamp test with arginine stimulation). The mean change in plasma insulin levels from Day 2 to Day 9 were calculated as Values on Day 9 - Values on Day 2.</description>
        <time_frame>0-10 mins, 10-180 mins, 0-180 mins (Day 2 and Day 9)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline hyperglycemic clamp test was conducted on Day 2 (pre-treatment) and a post-treatment hyperglycemic clamp was conducted on Day 9.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline hyperglycemic clamp test was conducted on Day 2 (pre-treatment) and a post-treatment hyperglycemic clamp was conducted on Day 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Area Under the Curve (AUC) of Plasma Insulin Level 0-10mins, 10-180mins, 0-180mins During Hyperglycemic Clamp</title>
          <description>Blood samples were taken at -30 min, -15 min, 0 min, 15 min, 30 min, 45 min, 60 min, 75 min, 90 min, 105 min, 120 min, 135 min, 150 min, 165 min, 180 min to assess the plasma insulin levels during Hyperglycemic Clamp (2-step hyperglycemic clamp test with arginine stimulation). The mean change in plasma insulin levels from Day 2 to Day 9 were calculated as Values on Day 9 - Values on Day 2.</description>
          <units>h*pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.07" spread="19.15"/>
                    <measurement group_id="O2" value="-27.95" spread="18.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 10-180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1450.59" spread="1237.44"/>
                    <measurement group_id="O2" value="-1474.65" spread="1009.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1478.65" spread="1254.66"/>
                    <measurement group_id="O2" value="-1502.60" spread="1022.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-10 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 10-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-10 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 10-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre and Post treatment Area Under the Curve (AUC) 0-180 minutes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Basal Endogenous Glucose Production (EGP)</title>
        <description>Change from Day 3 and Day 10 of Basal EGP (Hyperinsulinemic-Euglycemic Clamp)</description>
        <time_frame>Day 3 and Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Basal Endogenous Glucose Production (EGP)</title>
          <description>Change from Day 3 and Day 10 of Basal EGP (Hyperinsulinemic-Euglycemic Clamp)</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.041" spread="0.342"/>
                    <measurement group_id="O2" value="0.112" spread="0.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Basal EGP</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.608</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Basal EGP</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.132</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Low Dose % Endogenous Glucose Production (EGP) Inhibition</title>
        <description>Change from Day 3 and Day 10 of low dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)</description>
        <time_frame>Day 3 and Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Dose % Endogenous Glucose Production (EGP) Inhibition</title>
          <description>Change from Day 3 and Day 10 of low dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)</description>
          <units>percentage of EGP Inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.54" spread="23.47"/>
                    <measurement group_id="O2" value="-6.28" spread="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Low-Dose % EGP Inhibition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Low-Dose % EGP Inhibition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in High Dose % Endogenous Glucose Production (EGP) Inhibition</title>
        <description>Change from Day 3 and Day 10 of high dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)</description>
        <time_frame>Day 3 and Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High Dose % Endogenous Glucose Production (EGP) Inhibition</title>
          <description>Change from Day 3 and Day 10 of high dose % EGP Inhibition (Hyperinsulinemic-Euglycemic Clamp)</description>
          <units>percentage of EGP inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="15.65"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in high-dose % EGP Inhibition</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.573</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Low-Dose Glucose Disposal Rate (GDR)</title>
        <description>Change from Day 3 and Day 10 in Low-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.</description>
        <time_frame>Day 3 and Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low-Dose Glucose Disposal Rate (GDR)</title>
          <description>Change from Day 3 and Day 10 in Low-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="2.230"/>
                    <measurement group_id="O2" value="0.791" spread="2.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Low-Dose Glucose Disposal Rate (GDR)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.956</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Low-Dose Glucose Disposal Rate (GDR)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in High-Dose Glucose Disposal Rate (GDR)</title>
        <description>Change from Day 3 and Day 10 in High-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.</description>
        <time_frame>Day 3 and Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide 600 µg sc Bid</title>
            <description>Pasireotide 600 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide 900 µg sc Bid</title>
            <description>Pasireotide 900 µg was injected subcutaneously twice daily from Day 3-10. Baseline Hyperinsulinemic-Euglycemic Clamp was conducted on Day 3 (pre-treatment) and post-treatment on Day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-Dose Glucose Disposal Rate (GDR)</title>
          <description>Change from Day 3 and Day 10 in High-Dose Glucose Disposal Rate (GDR) during Hyperinsulinemic-Euglycemic Clamp.</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="2.051"/>
                    <measurement group_id="O2" value="-0.027" spread="2.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in High-Dose Glucose Disposal Rate (GDR)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.993</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in High-Dose Glucose Disposal Rate (GDR)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.956</p_value>
            <p_value_desc>Two sided P value.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) were collected in real time as reported by each study subject. The study Investigators' reviewed and evaluated each individually reported Adverse Event within one week of reporting (if not immediately upon report).</time_frame>
      <desc>The investigator provided a listing of each subject’s AEs. The individual AEs that occurred in each subject were then identified using the Investigator’s term and AE frequency was summarized by dose group and adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pasireotide 600 μg sc Bid</title>
          <description>Forty-five healthy male volunteers were randomized to receive pasireotide 600 μg (n=19), 900 μg (n=19) or 1200 μg (n=7) sc bid. All participants completed the study. Due to an increased severity of gastrointestinal AEs in the 1200 μg bid arm, randomization to this dose was discontinued after seven participants had completed the 7 days of treatment. These participants were included in the safety analyses only.</description>
        </group>
        <group group_id="E2">
          <title>Pasireotide 900 μg sc Bid</title>
          <description>Forty-five healthy male volunteers were randomized to receive pasireotide 600 μg (n=19), 900 μg (n=19) or 1200 μg (n=7) sc bid. All participants completed the study. Due to an increased severity of gastrointestinal AEs in the 1200 μg bid arm, randomization to this dose was discontinued after seven participants had completed the 7 days of treatment. These participants were included in the safety analyses only.</description>
        </group>
        <group group_id="E3">
          <title>Pasireotide 1200 μg sc Bid</title>
          <description>Forty-five healthy male volunteers were randomized to receive pasireotide 600 μg (n=19), 900 μg (n=19) or 1200 μg (n=7) sc bid. All participants completed the study. Due to an increased severity of gastrointestinal AEs in the 1200 μg bid arm, randomization to this dose was discontinued after seven participants had completed the 7 days of treatment. These participants were included in the safety analyses only.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>10 subjects (53.6%) in the 600 µg sc bid arm. 10 subjects (53.6%) in the 900 µg sc bid arm. 5 subjects (71.4%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal Cramping</sub_title>
                <description>6 subjects (31.6%) in the 600 µg sc bid arm. 9 subjects (47.4%) in the 900 µg sc bid arm. 4 subjects (57.1%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Loose Stools (soft stools)</sub_title>
                <description>5 subjects (26.3%) in the 600 µg sc bid arm. 13 subjects (68.4%) in the 900 µg sc bid arm. 2 subjects (28.6%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Burning Sensation</sub_title>
                <description>4 subjects (21.1%) in the 600 µg sc bid arm. 2 subjects (10.5%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>3 subjects (15.8%) in the 600 µg sc bid arm. 4 subjects (21.1%) in the 900 µg sc bid arm.
1 subjects (14.3%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting/emesis</sub_title>
                <description>2 subjects (10.5%) in the 600 µg sc bid arm. 3 subjects (15.8%) in the 900 µg sc bid arm. 3 subjects (42.8%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gas (Flatulence)</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm. 4 subjects (21.1%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Frequent Stools</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Light colored stool</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pressure in gut</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomach ache</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomach cramps</sub_title>
                <description>1 subject (5.3%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomach fullness</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>1 subject (5.3%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>3 subjects (15.8%) in the 600 µg sc bid arm.
1 subject (14.3%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Impacted wisdom tooth</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <description>1 subject (5.3%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>1 subject (14.3%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Histamine-like reaction</sub_title>
                <description>1 subject (14.3%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <description>1 subject (14.3%) in the 1200 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction while voiding</sub_title>
                <description>2 subjects (10.5%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infiltration, left ACFf</sub_title>
                <description>Procedural complication:
1 subject (5.3%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection (common cold)</sub_title>
                <description>1 subject (5.3%) in the 600 µg sc bid arm. 3 subjects (15.8%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site redness</sub_title>
                <description>2 subjects (10.5%) in the 600 µg sc bid arm. 2 subjects (10.5%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site stinging</sub_title>
                <description>2 subjects (10.5%) in the 600 µg sc bid arm. 2 subjects (10.5%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site bruise</sub_title>
                <description>1 subject (5.3%) in the 900 µg sc bid arm.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Veterans Medical Research Foundation</organization>
      <phone>858-552-8585</phone>
      <email>rrhenry@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

